| Artemether-lumefantrine (N = 475) | Sulphadoxine-pyrimethamine (N = 480) | |||
---|---|---|---|---|---|
Perinatal mortality (primary outcome) - n (%) | 20 (4.2) | 24 (5.0) | |||
   Asymptotic 95% CI | 2.4 - 6.0 | 3.1 - 6.9 | |||
   Pearson-Clopper 95% CI | 2.6 - 6.4 | 3.2 - 7.3 | |||
   Stillbirth - n (%) | 9 (1.9) | 13 (2.7) | |||
   Neonatal death ≤7 days after birth - n (%) | 11 (2.3) | 11 (2.3) | |||
 | Exposure to anti-malarial agent(s) during first trimester* | ||||
 | AL only (N = 135) | AL + SP (N = 7) | SP or/and quinine (N = 129) | None (N = 644) | Unknown (N = 40) |
Perinatal mortality - n (%) | 6 (4.4) | 1 (14.3) | 5 (3.9) | 31 (4.8) | 1 (2.5) |
   Stillbirth (>28 weeks gestation) | 2 (1.5) | 0 (0) | 3 (2.3) | 17 (2.6) | 0 (0) |
   Death ≤7 days after birth | 4 (3.0) | 1 (14.3) | 2 (1.6) | 14 (2.2) | 1 (2.5) |